carmustine has been researched along with Cutaneous T-Cell Lymphoma in 10 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 9.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 5.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "The two major topical treatment modalities for cutaneous T-cell lymphoma (CTCL) are mechlorethamine (nitrogen mustard) and topical carmustine (BCNU)." | 4.79 | Topical treatment of early cutaneous T-cell lymphoma. ( Meller, JA; Ramsay, DL; Zackheim, HS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tacastacas, JD | 1 |
| Chan, DV | 1 |
| Carlson, S | 1 |
| Gerson, SL | 1 |
| Dowlati, A | 1 |
| Fu, P | 1 |
| Lu, K | 1 |
| Groft, S | 1 |
| Rosenjack, J | 1 |
| Honda, K | 1 |
| McCormick, TS | 1 |
| Cooper, KD | 1 |
| Dummer, R | 1 |
| Foss, F | 1 |
| Dreno, B | 1 |
| Bagot, M | 1 |
| Zackheim, HS | 4 |
| Ramsay, DL | 1 |
| Meller, JA | 1 |
| Heald, PW | 1 |
| Glusac, EJ | 1 |
| Thomson, KF | 1 |
| Sheehan-Dare, RA | 1 |
| Wilkinson, SM | 1 |
| Muche, JM | 1 |
| Gellrich, S | 1 |
| Sterry, W | 1 |
| Duvic, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma[NCT00961220] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2010-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Based on changes in modified SWAT assessment, patient responses will be classified as complete clinical response (CCR), partial response (PR), stable disease (SD), or progressive disease (PD). SWAT provides an accurate and reproducible assessment of cutaneous disease involvement based on body surface area of involvement and lesional thickness.~CCR: No evidence of disease, 100% improvement for a duration of at least 4 weeks. PR: Greater than or equal to 50% decrease in SWAT score compared to baseline and improvement is maintained for at least 4 weeks. SD: Less than 50% decrease in SWAT score compared to baseline. PD: Increase of greater or equal to 25% of the SWAT score compared to baseline while the patient is actively taking the study drug" (NCT00961220)
Timeframe: Up to 2 weeks after completion of study treatment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Clinical Response-confirmed | Complete Clinical Response-unconfirmed | Partial Response | Progressive Disease | |
| Treatment (O6-benzylguanine, Carmustine) | 6 | 2 | 8 | 1 |
5 reviews available for carmustine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Treatment of cutaneous T-cell lymphoma.
Topics: Carmustine; Combined Modality Therapy; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Mechlo | 1994 |
Topical treatment of early cutaneous T-cell lymphoma.
Topics: Administration, Topical; Antineoplastic Agents, Alkylating; Carmustine; History, 20th Century; Human | 1995 |
Cutaneous T cell lymphoma: update of treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Beta Particles; | 1999 |
Treatment of cutaneous T-cell lymphomas.
Topics: Adjuvants, Immunologic; Administration, Topical; Antibodies, Monoclonal; Antineoplastic Agents; Anti | 2000 |
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biops | 2001 |
1 trial available for carmustine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemoth | 2017 |
4 other studies available for carmustine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Topics: Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dermatitis, Exfoliative; Erythem | 2006 |
Time to achieve clearing with topical carmustine.
Topics: Administration, Cutaneous; Carmustine; Humans; Lymphoma, T-Cell, Cutaneous; Remission Induction; Ski | 1993 |
Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Female; Humans; | 2000 |
Allergic contact dermatitis from topical carmustine.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents, Alkylating; Carmustine; Dermatitis, Allergic | 2000 |